Home

TG Therapeutics, Inc. (TGTX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about TG Therapeutics, Inc. (TGTX)

Go deeper and ask any question about TGTX

Company Performance

Current Price

as of Sep 13, 2024

$23.73

P/E Ratio

39.54

Market Cap

$3.67B

Description

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

Metrics

Overview

  • HQMorrisville, NC
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerTGTX
  • Price$23.73+2.33%

Trading Information

  • Market Cap$3.67B
  • Float89.12%
  • Average Daily Volume (1m)3,347,610
  • Average Daily Volume (3m)3,117,144
  • EPS$0.67

Company

  • Revenue$346.73M
  • Rev Growth (1yr)357.05%
  • Net Income$6.88M
  • Gross Margin88.60%
  • EBITDA Margin12.10%
  • EBITDA$8.89M
  • EV$2.73B
  • EV/Revenue7.88
  • P/E39.54
  • P/S10.91
Documents